Clinical trials: Adjuvant Drug Therapy
Esophageal Cancer, Surgery
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown.
- Conditions
- Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
- Trial name
- NCT04280822
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Neoplasms, Breast
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their…
- Trial name
- NCT00374322
- Testing
- lapatinib
- Where
- 439 sites in United States, Argentina and 31 more
- Volunteers
- 3,166 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with lymph node…
- Trial name
- NCT06996093
- Testing
- 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy, aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
- Where
- China
- Volunteers
- 2,508 people
- Sponsor
- Fudan University
Breast Cancer
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.
- Trial name
- NCT01289353
- Testing
- Carboplatin, 3D-RT or IMRT
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- NYU Langone Health
Hypovolemic Shock
A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent
This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest.
- Trial name
- NCT05251181
- Testing
- Normal Saline, Centhaquine
- Volunteers
- 430 people
- Sponsor
- Pharmazz, Inc.
Breast Cancer
Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy of Anthracycline and/or Taxane.
- Trial name
- NCT01662128
- Testing
- Xeloda
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.
Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.
- Trial name
- ATD (NCT06272799)
- Testing
- T-DM1 adjuvant
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Regina Elena Cancer Institute
Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
ADJUPANET is an open label, double arm, multicenter, phase 3 trial that aims to investigate the efficacy of systemic chemotherapy in locally resected aggressive pancreatic neuroendocrine tumors.
- Trial name
- ADJUPANET (NCT07591493)
- Testing
- Adjuvant chemotherapy with Capecitabine-Temozolomide, Active surveillance
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
IB-II Gastric Cancer
A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
This study employs a multicenter randomized controlled trial design, led by the First Affiliated Hospital of Air Force Medical University (Xijing Hospital) in collaboration with 10 other domestic medical institutions, for a total…
- Trial name
- NCT07788196
- Testing
- Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Colorectal Cancer
Gene Testing in Patients With Colon Cancer
RATIONALE: Analyzing the structure of genes found in a person's cancer cells may help doctors improve methods of treating patients with colon cancer.
- Trial name
- NCT00003571
- Testing
- mutation analysis, tumor replication error analysis
- Where
- 44 sites in United States
- Volunteers
- 300 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
The purpose of this study is to determine that adjuvant systemic chemotherapy is superior to adjuvant transcatheter arterial chemoembolization(TACE) in prolonging recurrence free survival（RFS） in patients after radical resection…
- Trial name
- NCT02584556
- Testing
- systemic chemotherapy, Transcatheter Arterial Chemoembolization
- Sponsor
- Guangxi Medical University
Breast Cancer
Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection
The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data.
- Trial name
- NCT05236387
- Testing
- 99m Tc-TM
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University
Advanced Ovarian Cancer
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour.
- Trial name
- IPLA-OVCA (NCT04065009)
- Testing
- Ropivacaine, Saline Solution
- Where
- Sweden
- Volunteers
- 220 people
- Sponsor
- Karolinska Institutet
Esophageal Cancer
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.
- Trial name
- NCT00400114
- Testing
- Irinotecan, Cisplatin, Radiation
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Gastric Cancer
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC).
- Trial name
- Neo-D2plus (NCT03961373)
- Testing
- Gastrectomy with D2 lymphadenectomy, Gastrectomy with D2plus lymphadenectomy
- Where
- Italy
- Volunteers
- 539 people
- Sponsor
- University of Siena
Lung Cancer
Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
The purpose of this study is to determine whether a combination of the drugs docetaxel (Taxotere ® ), plus vinorelbine (Navelbine ® ), will result in fewer side effects than cisplatin chemotherapy, thereby improving delivery of…
- Trial name
- NCT00675597
- Testing
- Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery.
- Conditions
- Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma
- Trial name
- NCT01958580
- Testing
- Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Oropharyngeal Cancer
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
To determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx.
- Trial name
- NCT02159703
- Testing
- TORS, Adjuvant Radiation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Stage I Breast Cancer
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can…
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00146562
- Testing
- Darbepoetin Alfa, Pegfilgrastim, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- Harold J. Burstein, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.